To include your compound in the COVID-19 Resource Center, submit it here.

Corgenix, GBI merging

Anti-phospholipid test developer and manufacturer CONX and diagnostics company Genesis Bioventures (GBI) signed a letter of intent

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE